Underuse of American College of Cardiology/American Heart Association Guidelines in hemodialysis patients

Renal Failure

Volumn 29, Issue 5, 2007, Pages 559-565

  Gowdak, Luís Henrique Wolff ^a   Arantes, Rodolfo Leite ^a   De Paula, Flávio Jota ^a   Krieger, Eduardo M ^a   De Lima, José Jayme Galvão ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cardiovascular disease; Drugs; End stage renal disease; Hemodialysis; Hypertension

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEART PROTECTION; HEMODIALYSIS; HIGH RISK POPULATION; HUMAN; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK MANAGEMENT; SMOKING;

CARDIOLOGY; CARDIOVASCULAR DISEASES; FEMALE; GUIDELINE ADHERENCE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; SOCIETIES, MEDICAL; UNITED STATES;

EID: 34547203212     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220701395002     Document Type: Article

References (17)

1. US Renal Data System. USRDS 2001 Annual Data Report. Bethesda, Md.: National Institutes of Health. National Institute of Diabetes and Digestive and Kidney Diseases, 2001.
2. Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis. 1998;32:853-906.
3. Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation. 2002;106:388-391.
4. Eagle KA, Brundage BH, Chaitman BR, et al. Guidelines for perioperative cardiovascular evaluation for noncardiac surgery. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Committee on Perioperative Cardiovascular Evaluation for Noncardiac Surgery. Circulation. 1996;93:1278-1317.
5. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
6. Tonelli M, Bohm C, Pandeya S, et al. Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am J Kidney Dis. 2001;37:484-489.
7. Chow FYF, Polkinghorne KR, Chadban SJ, et al. Cardiovascular risk factors in dialysis patients: A comparison of risk factors and cardioprotective therapy between 1996-2001. Nephrology. 2003;8:177-183.
8. Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol. 2003;42:201-208.
9. Manley H, Drayer DK, Muther RS. Medication-related problem type and appearance rate in ambulatory hemodialysis patients. BMC Nephrology. 2003;4:10. Available at: http://www.biomedcentral.com. Accessed December 15, 2006.
10. Talbert RL. Drug dosing in renal insufficiency. J Clin Pharmacol. 1994;34;99-110.
11. De Lima JJ, Sabbaga E, Vieira ML, et al. Coronary angiography is the best predictor of events in renal transplant candidates compared to noninvasive testing. Hypertension. 2003;42:263-268.
12. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2004;27(Suppl. 1):S5-S10.
13. th ed. Boston, Mass.: Little Brown; 1994.
14. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy, 1: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81-106.
15. The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI). A randomized placebocontrolled international trial. Eur Heart J. 1985;6:199-226.
16. The Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
17. Bailie GR, Eisele G, Liu L, et al. Patterns of medication use in RRI-CKD study: focus on medication with cardiovascular effect. Nephrol Dial Transplant. 2005;20:1110-1115.